Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
24 Juin 2022 - 1:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2022
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Celyad Oncology SA
On June 24, 2022, Celyad Oncology SA (the Company) issued a press release to announce leadership changes, a copy of which is attached
hereto as Exhibit 99.1 and is incorporated by reference herein. Effective immediately, the Board of Directors of the Company (the Board) has named Hilde Windels as Chairwoman of the Board, succeeding Michel Lussier.
Mr. Lussier has been named Interim Chief Executive Officer and Principal Executive Officer, succeeding Filippo Petti, who resigned as Chief Executive Officer and Chief Financial Officer to pursue other opportunities.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1, except for the quotes of
Michel Lussier and Hilde Windels contained in Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statements on Form F-3 (File
No. 333-248464) and Form S-8 (File No. 333-220737).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELYAD ONCOLOGY SA |
|
|
|
|
Date: June 24, 2022 |
|
|
|
By: |
|
/s/ Michel Lussier |
|
|
|
|
|
|
Michel Lussier Interim Chief Executive
Officer |
Celyad (CE) (USOTC:CLYYF)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Celyad (CE) (USOTC:CLYYF)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about Celyad SA (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Celyad Oncology Sa